Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology company’s stock last week. This is the first big Informative Sell transaction by Sahin this year.
BioNTech is a renowned pharmaceutical company that develops immunotherapies and vaccines for cancer and infectious diseases. The company rose to fame during the COVID-19 pandemic for its coronavirus vaccine Comirnaty, developed in partnership with U.S. pharma giant Pfizer (PFE).
A corporate insider’s share sale usually signals caution about the company’s future potential. However, an insider might sell shares for other reasons, such as financial or personal obligations. For instance, Sahin’s recent stock sale was related to common shares acquired by exercising certain stock options in August 2024.
A Closer Look at the Insider’s Transactions
As per Form 144 filed with the SEC, Sahin sold 1 million BNTX shares on February 20. At the same time, BioNTech COO Poetting Sierk also sold BNTX stock worth $14.35 million on February 20.
BNTX stock currently has a Very Negative Insider Confidence Signal on TipRanks, based on Informative Sell transactions worth $160.20 million undertaken in the last three months.
It is important to keep an eye on the Informative trades of corporate insiders, given their knowledge of a company’s growth potential. Interestingly, TipRanks offers daily insider transactions as well as a list of top corporate insiders. It also provides a list of hot stocks that boast either a Very Positive or Positive insider confidence signal.
Is BNTX a Good Stock to Buy?
Analysts remain highly bullish about BioNTech’s stock forecast. On TipRanks, BNTX stock commands a Strong Buy consensus rating based on 11 Buys and two Hold ratings. Also, the average BioNTech SE price target of $142.86 implies 19% upside potential from current levels. In the past year, BioNTech stock has gained 28.3%.
